Home
About
Overview
Sharing Data
ORCID
Help
History (8)
Schools, Public Health
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Glucosamine
alpha-Defensins
Immunogenicity of infliximab in Crohn's disease.
See All 8 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Immunogenicity of infliximab in Crohn's disease.
Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6.
View in:
PubMed
subject areas
Adjuvants, Immunologic
Antibodies
Antibodies, Monoclonal
Crohn Disease
Drug Administration Schedule
Drug Therapy, Combination
Gastrointestinal Agents
Humans
Infliximab
Tumor Necrosis Factor-alpha
authors with profiles
Stephen B. Hanauer